This peptide blend combines AOD-9604 for targeted fat loss, CJC-1295 for sustained growth hormone release, and Ipamorelin for selective growth hormone stimulation. It is typically administered subcutaneously once daily, with dosages gradually increasing over an 8-12 week cycle to support body composition improvements.
- Combines three distinct peptides for body composition effects.
- Gradual dose titration over the first few weeks.
- Preferably injected on an empty stomach to optimize GH release.
- Synergistic action targets both fat reduction and lean mass support.
- Requires reconstitution with 3.0 mL bacteriostatic water.
Reconstitution
Vial strength
12 mg
Bacteriostatic water
3 mL
Concentration
4 mg/mL
1 unit = 0.01 mL = 40 mcg total (20 mcg AOD + 10 mcg CJC + 10 mcg Ip)
- 1Draw 3.0 mL of bacteriostatic water with a sterile syringe.
- 2Slowly inject the water down the inside wall of the vial, avoiding foaming.
- 3Gently swirl or roll the vial until the powder completely dissolves; do not shake.
- 4Label the reconstituted vial with the date and store it in the refrigerator at 2-8 °C (35.6-46.4 °F), protected from light.
Dosing schedule
| Phase | Dose | On a U-100 syringe |
|---|---|---|
| Week 1 | 200 mcg AOD / 100 mcg CJC / 100 mcg Ip | 10 units (0.10 mL) |
| Week 2 | 300 mcg AOD / 150 mcg CJC / 150 mcg Ip | 15 units (0.15 mL) |
| Weeks 3-12 | 400 mcg AOD / 200 mcg CJC / 200 mcg Ip | 20 units (0.20 mL) |
Protocol detail
| Start | Begin with 0.10 mL daily (200 mcg AOD / 100 mcg CJC / 100 mcg Ipamorelin) and gradually increase by approximately 0.05 mL each week as tolerated. |
|---|---|
| Target | Aim to reach 0.20 mL daily (400 mcg AOD / 200 mcg CJC / 200 mcg Ipamorelin) by Week 3. |
| Frequency | Inject once per day subcutaneously. |
| Cycle Length | Recommended for 8-12 weeks, with an optional extension to 16 weeks based on individual goals. |
| Timing | Administer in the morning or before bed on an empty stomach. Remember to rotate injection sites regularly. |
Overview at a glance
| Goal | Support body composition improvements by combining fat-mobilizing and growth hormone-stimulating mechanisms. |
|---|---|
| Schedule | Daily subcutaneous injections for 8-12 weeks, with an option to extend to 16 weeks. |
| Dose Range | 200-400 mcg AOD / 100-200 mcg CJC / 100-200 mcg Ipamorelin daily, with gradual increases. |
| Reconstitution | Add 3.0 mL of bacteriostatic water to a 12 mg vial, resulting in a 4 mg/mL total concentration. |
| Storage | Lyophilized vials are frozen; reconstituted solution is refrigerated. Avoid repeated freezing and thawing. |
How it works
This peptide blend orchestrates body composition changes through a multi-pronged approach. AOD-9604, a fragment of human growth hormone, specifically targets and mobilizes stored fat without influencing insulin-like growth factor 1 (IGF-1) or glucose metabolism. CJC-1295 acts as a sustained growth hormone-releasing hormone (GHRH) analog, promoting prolonged elevation of both growth hormone and IGF-1. Ipamorelin, a selective ghrelin mimetic, stimulates the pulsatile release of growth hormone without also increasing cortisol or adrenocorticotropic hormone (ACTH). Collectively, these peptides enhance the body's natural growth hormone rhythms and foster favorable shifts in body composition, supporting reductions in fat mass and increases in lean muscle.
Reported effects
- Supports reduction in fat mass
- Enhances lipolysis (fat breakdown)
- May promote lean muscle gains
- Stimulates sustained growth hormone and IGF-1
- Selective growth hormone release, avoiding cortisol/prolactin increases
- Favorable safety profile observed with AOD-9604
Reported side effects
- Mild injection site reactions (redness, itching)
- Transient flushing or warmth
- Occasional headache or lightheadedness
- Mild water retention
Storage
Lyophilised (unmixed)
Store at -20 °C (-4 °F) in dry, dark conditions, minimizing moisture.
After reconstitution
Refrigerate at 2-8 °C (35.6-46.4 °F) and use within 28 days. Avoid freeze-thaw cycles.
Supplies
| Peptide vials | For an 8-week cycle, you'll need 4 vials; for 12 weeks, 6 vials; and for 16 weeks, 8 vials. |
|---|---|
| Insulin Syringes (U-100) | Plan for 7 syringes per week (1 per day). This translates to 56 for 8 weeks, 84 for 12 weeks, and 112 for 16 weeks. |
| Bacteriostatic Water (10 mL bottles) | You will need 3.0 mL per vial for reconstitution. For an 8 or 12 week cycle, 2 bottles suffice (12-18 mL total). For 16 weeks, 3 bottles (24 mL total). |
| Alcohol Swabs | Use two swabs daily—one for the vial stopper and one for the injection site. This means approximately 112 for 8 weeks, 168 for 12 weeks, and 224 for 16 weeks. |
Important notes
- Always use a new, sterile insulin syringe for each injection and dispose of it in a sharps container.
- Rotate injection sites (abdomen, thighs, upper arms) to minimize local irritation and tissue damage.
- Inject slowly and allow a few seconds before withdrawing the needle.
- Document your daily dose and injection site rotation to ensure consistency.
- Administer on an empty stomach for optimal growth hormone release.
Frequently asked questions
What is the primary benefit of combining AOD-9604, CJC-1295, and Ipamorelin?
The primary benefit of this blend is a synergistic effect on body composition. AOD-9604 targets fat loss, while CJC-1295 and Ipamorelin work together to enhance and sustain natural growth hormone production, promoting lean muscle gain and overall metabolic improvement.
How crucial is the 'empty stomach' timing for injections?
Injecting on an empty stomach is recommended because food, especially carbohydrates, can cause an insulin response which may blunt the body's natural growth hormone release. Administering the peptides when insulin levels are low helps optimize the growth hormone-stimulating effects.
Can I extend the cycle length beyond 12 weeks?
Educational protocols suggest cycle lengths of 8-12 weeks, with an optional extension up to 16 weeks. Always consider individual response and consult with a research professional if you plan to extend the protocol.
What kind of syringe should I use for administering this blend?
You should use a U-100 insulin syringe for precise dosing. For smaller doses (e.g., during titration), 30-unit or 50-unit insulin syringes may offer better readability compared to 100-unit syringes.
Educational reference only. These figures summarise how AOD-9604 + CJC-1295 + Ipamorelin is commonly described in research literature and supplier documentation, including the AOD-9604 + CJC-1295 + Ipamorelin listing at peptidesuk4u.co.uk. They are not a prescription, not medical advice, and not a recommendation to self-administer anything.
Related protocols
HGH 191AA (10IU Vial)
Recombinant human growth hormone for body composition and metabolic health.
CJC-1295 DAC + Ipamorelin Stack (5 mg (+ 5 mg))
Synergistic GH release for enhanced anabolic signaling and body composition.
Tesamorelin + Ipamorelin (10 mg Blend)
Synergistic blend for enhanced growth hormone release and fat reduction.
5-Amino-1MQ (10 mg Vial)
Inhibitor of NNMT for metabolic support and fat metabolism.